Full Press Release Details
Eyenovia Prices Public Offering of Common
NEW YORK, New York - December
19, 2018 - Eyenovia, Inc. ("Eyenovia" or the "Company") (NASDAQ: EYEN), a clinical stage
ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print technology,
has priced its underwritten public offering of 1,200,000 shares of common stock at an offering price of $2.45 per share. In addition,
Eyenovia has granted the underwriter a 45-day option to purchase up to an additional 180,000 shares to cover over-allotments, if
any. All of the shares are being offered by the Company.
The Company expects to receive gross proceeds
from the offering, excluding the exercise of the over-allotment option, if any, of approximately $2.9 million, excluding underwriting
discounts and commissions and other offering-related expenses. Assuming the full exercise of the over-allotment option, the gross
proceeds may reach approximately $3.4 million.
The Company intends to use the net proceeds
from the offering to initiate Phase III clinical trials for MicroPine and MicroProst, complete formulation work for each development
program, and for general corporate purposes, including working capital. The offering is expected to close on or about December
21, 2018, subject to the satisfaction of customary closing conditions.
National Securities Corporation, a wholly
owned subsidiary of National Holdings Corporation (NASDAQ: NHLD) is acting as sole book-running manager for the offering.
A registration statement on Form S-1 relating
to the shares of common stock being offered was filed with the Securities and Exchange Commission (the "SEC") and is
effective. Copies of the final prospectus relating to this offering may be obtained, when available, by request to the offices
of National Securities Corporation, Attention: Christopher Passarelli, 200 Vesey Street, 25th Floor, New York, New York 10281,
telephone: (212) 417-8164 or by email at prospectusrequest@nationalsecurities.com; or on the SEC's website at http://www.sec.gov.
This announcement shall not constitute
an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any offer or sale of these securities
in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful.
About Eyenovia, Inc.
Eyenovia, Inc. (NASDAQ: EYEN) is a
specialty biopharmaceutical company building a portfolio of next generation topical eye treatments based on its proprietary delivery
and formulation platform for microdosing. Eyenovia's pipeline is currently focused on the late-stage development of microdosed
medications for myopia progression, glaucoma, mydriasis and other eye diseases.
Forward-Looking Statements
Except for historical information, all
of the statements, expectations, and assumptions contained in this press release are forward-looking statements. Forward-looking
statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions
or any other statements relating to our future activities or other future events or conditions. These statements are based on current
expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements
are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore,
actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking
statements due to numerous factors discussed from time to time in documents which we file with the SEC. In addition, such statements
could be affected by risks and uncertainties related to, among other things, market conditions, the satisfaction of customary closing
conditions for the proposed offering, and other risks and uncertainties described in the registration statement filed with the
SEC. Any forward-looking statements speak only as of the date on which they are made, and except as may be required under applicable
securities laws, we do not undertake any obligation to update any forward-looking statements.
Chief Financial Officer
Tram Bui / Alexander Lobo
Phone: 646-536-7035/7037